Europe Single-use Bioreactors Market by Product [Systems, Media Bags (2D, 3D), Filtration Assemblies], Type [Stirred Tank, Wave Induced], Cell [Mammalian, Bacterial, Yeast], Application [Commercial (Mab, Vaccine), Research], End User - Forecast to 2030

The Europe Single-use Bioreactors Market is projected to reach $3.34 billion by 2030, at a CAGR of 15.3% from 2024 to 2030. Single-use bioreactors, also called disposable bioreactors, are made of disposable bags instead of a culture vessel. These bioreactors eliminate the need for expensive and bulky clean-in-place (CIP) or steam-in-place (SIP) systems and offer flexibility and a low risk of contamination, contributing to their adoption by pharma & biotech companies. Along with this, end users' manufacturing and R&D capacity expansion increases the demand for the products in the region. For instance, in September 2022, Viralgen Vector Core (Viralgen), a member of the Bayer worldwide group of companies, received Certified Good Manufacturing Practices (cGMP) certification for human medicinal products, investigational medicinal products, and sterile or biologically active substances.

The rapid adoption of disposable technology in the pharmaceutical and biotechnology industry, growing demand for biopharmaceuticals, government support for the production & use of biopharma products for various health indications, and capacity expansion of biopharmaceutical plants are some of the major factors driving the growth of the Europe single-use bioreactors market.

Click here to: Get a Free Sample Copy of this Report

Expansion of Manufacturing Capacity by CDMOs & CROs and Increasing Interest of U.S. Companies to Invest in European Companies are Driving the Growth of this Market

Rising demand for biologicals and biosimilars; the rising cost of drug development; the growing demand for cell therapies, gene therapies, and personalized medicines; and the growing consolidation among CDMOs & CROs supported the adoption of single-use bioreactors for end users in the region.

CDMOs support pharmaceutical & biotechnology firms through outsourced research and manufacturing services on a contractual basis. Pharmaceutical and biopharmaceutical companies depend on CDMOs to reduce R&D efforts, avoid the high fixed costs of in-house development, and harness the manufacturing capabilities and expertise required to drive their molecules through clinical development. These organizations offer a broad range of services in preclinical research, clinical research, assay development, clinical trial management, and bioproduction.

Pharmaceutical & biopharmaceutical companies are increasingly adopting drug discovery outsourcing to reduce the overall drug development time & related costs, improve R&D productivity, optimize operational flexibilities, and increase their profit margins. Looking at the growing market of CDMOs, various key players in the life science industry are taking steps toward acquiring CDMOs. In May 2024, eureKING (France) acquired Skyepharma (CDMO) (France) to build biotherapies segments and expand its biomanufacturing capacity. The acquisitions of CDMOs by large companies lead to the expansion of the capacities of CDMOs, which in turn is beneficial for the single-use bioreactors market. Also, the expansion by CDMOs for biomanufacturing supports the growth of this segment. For instance,

• In July 2021, Viralgen VC (Spain) opened its new manufacturing facility in Basque, Italy. This facility is associated with adeno-associated virus gene therapy production.
• In July 2021, Catalent, Inc. (U.S.) invested USD 100 million to expand the capacity of a facility in Anagni, Italy, by adding biological drug substance manufacturing capabilities.

Thus, such expansion increases demand for biopharma products, thereby driving the Europe single-use bioreactors market for these end users.

Government Initiatives to Increase Bioproduction is an Opportunity for the Players in this Market

European governments are investing in the pharma & biopharma industry to boost R&D and bioproduction. The government and other public groups and enterprises are providing funding and grants for research and development to pharmaceutical, biopharmaceutical, and biotech companies, thereby helping to grow the biopharmaceutical market and increasing demand for single-use bioreactors. For instance,

• In 2021, the U.K. Biotechnology and Biological Sciences Research Council (BBSRC), which provides USD 101 million (GBP 57 million) each year for R&D in biotechnology and biological sciences, has adopted a new strategy for investment. Along with this strategy, the U.K. government aims to increase R&D spending to 2.4% of gross domestic product by 2027.

• In 2021, the Government of Ireland allocated USD 975.2 billion (EUR 869.2 billion) for research and development to software, medical devices, manufacturing, and pharmaceutical companies.
• In 2021, the Prime Minister of the U.K. hosted an event with large biopharmaceutical companies, including AstraZeneca (U.K.), GlaxoSmithKline (U.K.), and Pfizer (U.K.), to strengthen future pandemic responses. This summit was after announcing new investments, which swooped in USD 6.7 billion (GBP 5 billion) from July 2021 to December 2021.
• In 2021, the Irish government provided funding of USD 4.9 billion (EUR 4 billion) for R&D to ICON plc (Ireland), a drug development solutions and services provider to the pharmaceutical, biotechnology, and medical device industries. This funding was awarded for clinical trials to expand patient access to clinical research through technology.

Key Findings in the Europe Single-use Bioreactors Market Study:

Among Products, the Media Bags Segment is Projected to Register the Highest CAGR

Advantages like high flexibility, low levels of extractable and leachable and high product stability during storage compared to culture vessels supported the market growth. Also, the low risk of cross-contamination from batch to batch and product to product and eliminating the time and expense of sterilization-in-place (SIP) & clean-in-place (CIP) operations, optimizing capacity utilization, increase their adoption for bioprocessing.

Among Types, the Wave-induced Bioreactors Segment is Projected to Register the Highest CAGR

Wave-induced bioreactor systems offer various benefits, like no need to rely on oxygen bubbles for culture aeration, generation of rocking motion to meet the required amount of oxygen for cell growth, and a large surface-to-volume ratio. These benefits lead to driving the market at the highest growth rate.

In contrast to conventional stirred tank bioreactors, wave-induced bioreactor systems improve fluid turnover and minimize shear forces compared to stirred tanks. Such flow conditions reportedly produce better cell suspension and reduce the risk of cell damage and thus have enabled rocking-motion bioreactors to reach higher maximum cell densities than traditional spinner flasks.

Among Cell Types, in 2024, the Mammalian Cells Segment is Expected to Account for the Largest Share

In 2024, the mammalian cells segment is expected to account for the largest share of the market. Increased need for mAbs production with consistent quality and preference for culturing in large-scale suspension bioreactors to increase bioproduction supported the share. Also, Demand for high throughput operations in cell culture processing will continue to drive the single-use bioreactor market for mammalian cells.

The Research Bio-production Segment is Projected to Register the Highest CAGR

Among the application, the research bio-production segment is projected to register the highest CAGR owing to growing support from regulatory agencies & companies’ initiatives. For instance, in January 2021, the Circa Group Europe Limited (Ireland) invested USD 2.2 billion (EUR 2 billion) in biopharmaceutical research and development through IDA Ireland’s client companies annually. Thus, such an investment plan helps boost the demand for biopharma products in the European region, thereby driving the market.

Among End Users, in 2024, the Pharmaceutical & Biopharmaceutical Companies Segment is Expected to Account for the Largest Share of the Market

The large market share of this segment is attributed to the rise in R&D activities, the focus of U.S.-based companies to expand their manufacturing capacities in European countries, the high adoption of bioreactors in pharmaceutical laboratories, and concerns over flexibility, sterility, cost efficiency, and enhanced productivity.

Also, increasing demand for biopharmaceutical products, growing adoption of single-use products, growing incidence & prevalence of various chronic diseases, rising R&D expenditure by pharmaceutical & biotechnology companies, and recent launches of biologics for chronic & rare diseases raise the growth of the market for them.

Germany: In 2024, to Account for the Largest Share of the Market

The factors supporting the large share of this market include increasing pharmaceutical export, government grants, growth in immunization, and funding to biotech & biopharmaceutical companies expanding their capacities for biologics to meet the market's increasing demand. Being one of the largest biopharma markets in the EU region and the presence of key players in the country supported their large share in the market.

Key Players

The report includes a competitive landscape based on an extensive assessment of the key growth strategies adopted by leading market participants in the last 3 to 4 years. The key players profiled in the Europe single-use bioreactors market report are Merck KGaA (Germany), Danaher Corporation (U.S.), Sartorius AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Eppendorf AG (Germany), Solaris Biotechnology srl (Italy), Cellexus International Ltd. (U.K.) CESCO Bioengineering Co., Ltd. (Taiwan), PBS Biotech, Inc. (U.S.), Solida Biotech GmbH (Germany), and Infors AG (Switzerland).

Scope of the Report:

Europe Single-use Bioreactors Market, by Product

• Single-use Bioreactor Systems
  • Upto 10L
  • 11L-500L
  • 501-1000L
  • Above 1001L
• Media Bags
  • 2D
  • 3D
  • Linear
• Filtration Assemblies
• Other Products
  (Note: Other products include pumps, single-use vessels, tubing & connectors, gas components, rockers, cables, sensors/probes, and films.)

Europe Single-use Bioreactors Market, by Type

• Stirred-tank Bioreactors
• Wave-induced Bioreactors
• Other Types
  (Note: Other types include hybrid bioreactors, bubble-column, and bioreactors with vertically perforated discs.)

Europe Single-use Bioreactors Market, by Cell Type

• Mammalian cells
• Bacterial Cells
• Yeast Cells
• Other Cell Types
  (Note: Other cell types include plant cells and insect cells.)

Europe Single-use Bioreactors Market, by Application

• Commercial Bioproduction
  • Monoclonal Antibody Production
  • Vaccine Production
  • Therapeutic Protein Production
  • Cell & Gene Therapy
• Research Bioproduction

Europe Single-use Bioreactors Market, by End User

• Pharmaceutical and Biopharmaceutical Companies
• Contract Development and Manufacturing Organizations (CDMO) and Contract Research Organizations (CROs)
• Academic and Research Institutes

Europe Single-use Bioreactors Market, by Country

• Germany
• U.K.
• France
• Italy
• Switzerland
• Ireland
• Denmark
• Belgium
• Spain
• Rest of Europe

Key questions answered in the report: